The REGENCY Trial evaluates Obinutuzumab, a type II anti-CD20 monoclonal antibody, in Class III and IV Lupus Nephritis (LN). This episode dives into:

• The mechanism of B-cell depletion therapy in lupus nephritis
• Study results comparing Obinutuzumab + standard therapy vs. standard therapy alone
• Effects on renal response, proteinuria reduction, and steroid-sparing benefits
• The future role of targeted biologics in lupus nephritis treatment

Episode 1: ESCAPE-MeVO Trial – A New Era in Stroke Treatment

The ESCAPE-MeVO Trial investigates whether endovascular thrombectomy improves outcomes in patients with medium vessel occlusions (MeVOs) in acute ischemic stroke. This episode explores:

• Why MeVOs are a unique challenge in stroke treatment
• How thrombectomy compares to standard medical management
• Key findings on patient outcomes, functional recovery, and complications
• Implications for stroke management and future guidelines